These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35871032)

  • 1. Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
    Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A
    Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
    Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
    Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
    Abay M; Ozgen L; Yalcin Y; Ozerkan K
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    van den Berg CB; Dasgupta S; Ewing-Graham PC; Bart J; Bulten J; Gaarenstroom KN; de Hullu JA; Mom CH; Mourits MJE; Steenbeek MP; van Marion R; van Beekhuizen HJ
    Gynecol Oncol; 2024 Aug; 187():113-119. PubMed ID: 38759517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
    Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
    J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I
    Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
    Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
    Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.